For these reasons, endoxifen is currently being investigated as a novel endocrine therapy for the treatment of estrogen receptor (ER)α–positive breast cancers and phase I and II clinical trials (NCT02311933, NCT01327781, and NCT01273168) have been done. This evidence concerns the gene ESR1 and breast carcinoma.